The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance
Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. Cell Metab. 2015;21(3):443–454. View source ↗
This is the discovery paper for MOTS-c. The authors identified a short open reading frame within the mitochondrial 12S rRNA that encodes a 16-amino-acid peptide, which they named MOTS-c. In skeletal muscle cell culture, MOTS-c was associated with increased glucose uptake and activation of AMP-activated protein kinase (AMPK). The proposed upstream mechanism was inhibition of the folate cycle, leading to accumulation of the AICAR intermediate — a known direct AMPK agonist. In mouse models, MOTS-c administration was associated with attenuation of high-fat-diet-induced obesity, improved insulin sensitivity on glucose and insulin tolerance testing, and reduced age-dependent insulin resistance. Endogenous circulating MOTS-c was detected in mouse and human plasma, supporting the authors' framing of MOTS-c as a mitochondrially-encoded signaling peptide.
Scientists discovered a tiny protein hidden inside a piece of mitochondrial DNA that no one had previously recognized as a gene. They named it MOTS-c. When they tested it in muscle cells, the cells took in more glucose and activated a master energy-sensing switch called AMPK — the same switch that exercise and the diabetes drug metformin flip on. When they gave MOTS-c to mice on a high-fat diet, the mice gained less weight and handled blood sugar better than untreated mice. Older mice also became more responsive to insulin. The discovery was significant because it showed that mitochondria — long thought of as just cellular power plants — also send chemical messages to the rest of the cell.
